证券时报记者 陈澄 数据显示，截至2024年末，药明康德整体活跃客户约6000家。其中，持续经营业务截至年末活跃客户约 5500家，持续经营业务全年新增客户约1000家，全球各地客户对公司服务的需求持续增长。截至2024年 末，公司持续经营业务在手订单493.1亿元，同比增长47.0%。 7月10日晚间，药明康德（603259）发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元， 同比增长约20.64%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。 分析人士认为，药明康德业绩与全球制药行业发展以及新药研发投入密切相关，在全球制药行业蓬勃发 展的推动下，公司的主营业务有着广阔的发展空间，伴随着全球各国经济的发展、全球人口总量的增 长、人口老龄化程度的提高、科技进步、医疗开支上升以及大众对于健康生活的需求不断增强，预计全 球制药市场规模以及对于医药研发服务的需求仍然将持续增长。 药明康德在半年度业绩预告中表示，公司持续聚焦独特的"一体化、端到端"CRDMO（合同研究、开发 与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工艺 和提高经营 ...

Core Viewpoint - WuXi AppTec focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, aiming to meet customer empowerment needs and continuously expand capabilities and production capacity, leading to steady business growth and improved operational efficiency [1][2]. Financial Performance Summary - The adjusted net profit attributable to the parent company is approximately RMB 631.48 million, representing a year-on-year increase of about 44.43% [1][2]. - Revenue from continuing operations is expected to grow by approximately 24.24% [2]. - The total profit for the period is estimated at approximately RMB 990.74 million, reflecting a year-on-year increase of about 101.92%, which includes investment income from the sale of part of the equity in an associated company [2][3]. - Basic earnings per share are expected to be approximately RMB 3.01, a year-on-year increase of about 106.16% [1]. Previous Year Performance Comparison - In the same period last year, the company reported revenue of RMB 1,724.09 million and an adjusted net profit of RMB 437.22 million [2]. - The basic earnings per share for the previous year were RMB 1.46 [2]. Reasons for Performance Increase - The main driver for the performance increase is the company's focus on its unique CRDMO business model, which has led to continuous optimization of production processes and enhanced operational efficiency [2]. - The non-operating income primarily stems from the sale of shares in WuXi XDC Cayman Inc., with expected gains of approximately RMB 320.99 million [3].